View More Recent Stories
-
Guggenheim Starts Keros Therapeutics (KROS) at Buy
-
Piper Sandler Reiterates Overweight Rating on Keros Therapeutics (KROS)
-
Keros Therapeutics (KROS) Announces Leadership Updates
-
Keros Therapeutics (KROS) Presents Clinical Data from KER-050 Program

